Q-omics provides the consensus-scored KBTBD4 profile across patient tissues and cancer cell-line models. KBTBD4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KBTBD4 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, KBTBD4 RNA expression shows 20,638 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where KBTBD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KBTBD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KBTBD4 survival associations across molecular data types. KBTBD4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KBTBD4 RNA expression–survival associations across cancer types. High KBTBD4 expression shows unfavorable associations in UVM and LUSC, but favorable associations in KIRC, UCS, HNSC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KBTBD4 RNA expression.
This table summarizes KBTBD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KBTBD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KBTBD4 shows lower tumor expression in THCA, LUAD, KIRC and KIRP and higher tumor expression in LIHC and BRCA. The THCA box plot shows higher KBTBD4 RNA expression in normal versus tumor tissue (log2 FC = −0.567, t-test p = .002).
This table shows molecular features associated with KBTBD4 in patient tissues and cancer cell lines. In patient samples, KBTBD4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KBTBD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
